Lancet Diabetes & Endocrinology

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	787
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	676
South Africa to produce insulin for Africa in 2024	653
Artificial intelligence and diabetes: time for action and caution	546
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	502
Anand Hardikar: a scientific nomad searching for the truth	483
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	479
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	459
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	431
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	420
Reassessing driving safety in diabetes	406
Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	360
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	305
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	246
Obesity in people living with type 1 diabetes	242
Implications of technology guidelines for low-income and middle-income countries	232
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	204
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	199
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	191
Better testing and labelling of drugs for people with obesity	179
A framework for improving diabetes care in humanitarian emergencies	170
World Health Assembly ratifies first global diabetes targets	166
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	165
What's preventing us from curbing the obesity crisis?	159
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	154

Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	154
What does renal failure teach us about our National Health System?	152
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	152
Putting wellbeing at the core of diabetes care	146
A roadmap for integrating mental health and diabetes services	145
Glycaemic index as part of the diabetes prevention strategy	136
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	136
Healthy weight for the next generation's health in China	133
The urgent need for a diabetes data rights charter	132
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	130
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	130
The promise and hope of GLP-1 receptor agonists	124
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	124
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	120
Lebanon: insulin out of reach after subsidies lifted	119
Jennifer Manne-Goehler: at the crossroads of pandemics	108
Rising diabetes diagnosis in long COVID	107
The role of nurses in diabetes care: challenges and opportunities	107
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	106
Challenging diabetes stigma starts and ends with all of us	101
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	100
The changing character of diabetes complications	97
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	97
Childhood obesity: a growing pandemic	93
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	91
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss	88
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	87
The uncomfortable truth about kidney disease in type 1 diabetes	83
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	83
CONCEPTT to care: the science of implementation in diabetes care	83
Understanding the mechanism of prediabetes remission in young people	82
Hypothalamic obesity: from basic mechanisms to clinical perspectives	81
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	77
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	77
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	77
Homing in on the causes of male infertility	76
Male hypogonadism: pathogenesis, diagnosis, and management	76
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	75
Women in diabetes research: stepping towards equity	75
Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019	73
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	72
Gender equality: timely and timeless	72
Improving HbA1c levels with advanced hybrid closed-loop therapy	72
Diabetes: knowing your risk matters	72
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	71
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	71
Blood pressure control according to type 2 diabetes status	69
Is it time to re-assess the development of thyroid function reference ranges?	68
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	67
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	66

Glucagon, from past to present: a century of intensive research and controversies	65
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	65
Diagnosing diabetes in African populations: a twist in the tale	64
Improving support for university students with type 1 diabetes	64
Embracing community sport to promote global health	62
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	61
Has the WHO Model Essential Medicines List lost its way?	61
SGLT-2 inhibitors: does it matter if they prevent type 2 diabetes	60
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	60
Screening type 1 diabetes and celiac disease by law	60
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	60
Corrections to Lancet Diabetes Endocrinol 2022; 10: 120–28	59
Central diabetes insipidus from a patient's perspective	58
On the occasion of International Women's Day	56
Vitamin D and fractures	56
Chronicling insulin from discovery to crisis	55
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	55
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	54
Teplizumab approval for type 1 diabetes in the USA	54
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	54
Management of menopause: a view towards prevention	54
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	54
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	53
Automated insulin delivery postpartum: insights from the AiDAPT study extension	53
Young adult-onset type 2 diabetes heralds a poor prognosis	53
More options for young children with type 1 diabetes	52
Technology for type 1 diabetes: what impact will it have?	52
How do clinicians integrate oral octreotide into their treatment plan for acromegaly?	50
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	50
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	50
Methodological considerations in D-health cancer mortality results – Authors' reply	50
Insulin regimens during type 1 diabetes pregnancy	49
Steps to redressing an imbalance: GLP-1 analogues for obesity in east Asia	48
Blood glucose targets in the critically ill: is one size fits all still appropriate?	47
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	47
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	46
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	46
Impact of higher BMI on cardiometabolic risk: does height matter?	46
Redefining obesity: advancing care for better lives	45
ORION-3: delivering lipid lowering treatment for longer	45
MarÍa José Redondo: rethinking type 1 diabetes	45
Addressing health and demographic challenges in Japan's ageing society	44
An inclusive approach to people with disabilities in diabetes care and education	43
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	42
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	41
Viswanathan Mohan: a dynasty of diabetology	41
Enhancing global access to diabetes medicines: policy lessons from the HIV response	41
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	41
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	40
Creating diabetes guidelines for the individual not just the illness	40
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	40
Is the impact of add on heart failure therapy influenced by background therapy?	40
How clinically relevant is statin-induced diabetes?	39
Disparities in fragility fracture and osteoporosis care in Africa	39
RETRACTED: Targeting of vitamin D supplementation to individuals with deficiency	38
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	38
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	38
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	38
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	38
From reproduction to metabolism: FSH as a key modulator in menopause	38
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	37
Risks and burdens of incident diabetes in long COVID: a cohort study	37
The growing global burden of thyroid cancer overdiagnosis	37
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	37
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	36
Iodine deficiency in Europe: vigilance and action required	35
Disease modifying therapies in diabetes and endocrinology	35
Setmelanotide: new promise for the treatment of hypothalamic obesity?	34
The potential role for artificial intelligence in fracture risk prediction	34
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	34
From prominent corneal nerves to multiple endocrine neoplasia type 2B	34
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	33
Sleep: a neglected public health issue	33
Improving type 1 diabetes care globally: the importance of medical education	33
Incretins and the cardiovascular system: bridging digestion with metabolism	32
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	32
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	32
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	31
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	31
What's in a decade?	31

Data processing in the DMagic cluster randomised controlled trial	31
Diabetes and the WHO Model List of Essential Medicines	30
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	28
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	28
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	28
Mendelian randomisation and vitamin D: the importance of model assumptions	28
Sex differences in familial hypercholesterolaemia	27
Osteoporosis in men	27
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	26
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	26
Maternal thyroid hypofunction and gestational diabetes risk	26
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	25
The double burden of poor diets	25
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	25
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	25
Revisiting osteoporosis guidelines	25
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	24
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial	24
Prevention of diabetes mortality at ages younger than 25 years: access to medications and high-quality health care	24
Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial	24
Bariatric surgery in children with obesity and type 2 diabetes	23
From research to policy: still a long way to go	23
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	22
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	22
Endocrine health in survivors of adult-onset cancer	22
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	22
Addressing the educational needs of older adults with type 1 diabetes	21
Peripheral CB1 receptor blockade for treatment of obesity	21
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	21
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	21
Sexual dimorphism in COVID-19: potential clinical and public health implications	20
PFAS: here today—here tomorrow	20
The power of resilience	20
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	19
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	19
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	19
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	19
A global plastics treaty to protect endocrine health	19
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	18
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	18
Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial	18
Does tirzepatide treatment improve skeletal muscle composition?	18
Trends in the incidence of young-adult-onset diabetes by diabetes type: a multi-national population-based study from an international diabetes consortium	18
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality – Authors' reply	18
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	18
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	18
The voices of lived experience in diabetes and endocrinology	17
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	17
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial	17
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	17
COVID-19 targets human adrenal glands	16
Predicting and preventing heart failure in type 2 diabetes	16
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	16
Statins for Graves' orbitopathy: a new tool for prevention and treatment?	16
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	16
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	16
The evidence for achondroplasia in 1st century AD Italy	15
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada	15
Halving heart failure outcomes by finerenone-mediated type 2 diabetes prevention	15
Food additive emulsifiers and risk of type 2 diabetes	15
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, paralle	15
Osteoporosis in the USA: prevention and unmet needs	14
Is autonomous cortisol secretion sexually dimorphic?	14
Diabetes educators: rewriting the narrative	14
Metabolic health and cardiometabolic risk clusters: implications for prediction, prevention, and treatment	14
Migrant health: a global responsibility	14
Endpoints for clinical trials in type 1 diabetes drug development	13
Correction to Lancet Diabetes Endocrinol 2023; 11: 567–77	13
The ISPAD Clinical Practice Consensus Guidelines 2022: how far we have come and the distance still to go	13
Roux-en-Y gastric bypass, adjustable gastric banding, or sleeve gastrectomy for severe obesity (By-Band-Sleeve): a multicentre, open label, three-group, randomised controlled trial	13
Heart failure: now centre-stage in diabetes	13
Vitamin D and acute respiratory infections: a definitive answer?	13
The obesity drug craze in Brazil	13
The actual burden of obesity—accounting for multimorbidity	13
Access to insulin and diabetes care in the Philippines	13
Denosumab in the treatment of osteoporosis associated with chronic kidney disease	12
Causes, prevention, and management of diabetes-related foot ulcers	12
Khalida Ismail: merging diabetes and mental health	12
Diabetes and frailty in an ageing world	12
Harmonising terminology for type 1 diabetes: the EDENT1FI lexicon initiative	12
The enduring effect of the COVID-19 pandemic on diabetes	12
Why does visceral adiposity not explain higher type 2 diabetes prevalence in Asian Indians?	12
Closed-loop systems: a bridge to cell therapy for type 1 diabetes?	12
Alarming rise in young-onset type 2 diabetes	12
Lancet Diabetes & Endocrinology Commission on the Definition and Diagnosis of Clinical Obesity	12
Polycystic ovary syndrome	12
Bariatric tourism	12
Effect of COVID-19 restrictions on thyroid cytopathology: delay in the diagnosis of indeterminate lesions	11
Carmella Evans-Molina: being of service	11
Melatonin: is it really a cardiovascular wonder pill for shift workers?	11
Answering clinically pertinent questions with real-world data from paediatric type 1 diabetes registries	11
Prequalification of insulin: what is missing?	11
Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	11
Diabetes education: the key to a brighter tomorrow	11